In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery.

Clark, Jeremy; Tong, Steven Y C

Clark, Jeremy; Tong, Steven Y C.

Afiliación

Clark J; Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (J.C., S.Y.T.).
Tong SYC; Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (J.C., S.Y.T.).

Ann Intern Med ; 176(5): JC52, 2023 05.

Article en En | MEDLINE | ID: mdl-37126816

RESUMEN

SOURCE CITATION: McCarthy MW, Naggie S, Boulware DR, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329:296-305. 36633838.

Asunto(s)

COVID-19; Fluvoxamina; Humanos; Fluvoxamina/uso terapéutico; Fluvoxamina/efectos adversos; Pacientes Ambulatorios; Tratamiento Farmacológico de COVID-19; Método Doble Ciego

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fluvoxamina / COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Intern Med Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google